Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group, J. Clin. Oncol, vol.14, pp.869-877, 1996. ,
Trends in survival for patients with metastatic soft-tissue sarcoma, Cancer, vol.117, pp.1049-1054, 2011. ,
NCCN Clinical Practice Guidelines in Oncology, J. Natl. Compr. Canc. Netw, vol.16, pp.536-563, 2018. ,
Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity, Nat. Med, vol.16, pp.781-787, 2010. ,
URL : https://hal.archives-ouvertes.fr/inserm-02438669
Monogenic and polygenic determinants of sarcoma risk: an international genetic study, Lancet Oncol, vol.17, pp.1261-1271, 2016. ,
Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors, Science, vol.347, pp.273-277, 2015. ,
Identification of new alternative lengthening of telomeres (ALT)-positive cancer cell lines using the C-circle assay, Proceedings of the 106th Annual Meeting of the American Association for Cancer Research (AACR), 2015. ,
, Cancer Res, vol.75, p.3768, 2015.
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors, Adv. Enzyme Regul, vol.22, pp.27-55, 1984. ,
Phase I trial of a first-in-class ATR inhibitor VX-970 as monotherapy (mono) or in combination (combo) with carboplatin (CP) incorporating pharmacodynamics (PD) studies, J. Clin. Oncol, vol.34, p.2504, 2016. ,
A Phase I dose-escalation study of ATR inhibitor monotherapy with AZD6738 in advanced solid tumors (PATRIOT Part A), Proceedings of the American Association for Cancer Research (AACR) Annual Meeting, vol.77, p.84, 2017. ,
Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand, J. Hematol. Oncol, vol.12, p.43, 2019. ,
An ATR and CHK1 kinase signaling mechanism that limits origin firing during unperturbed DNA replication, Proc. Natl. Acad. Sci. USA, vol.116, pp.13374-13383, 2019. ,
Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes, Am. J. Pathol, vol.179, pp.1608-1615, 2011. ,
Cancer Cells with Alternative Lengthening of Telomeres Do Not Display a General Hypersensitivity to ATR Inhibition, Front. Oncol, vol.6, p.186, 2016. ,
Unravelling mechanisms of p53-mediated tumour suppression, Nat. Rev. Cancer, vol.14, pp.359-370, 2014. ,
Targeting ATR in DNA damage response and cancer therapeutics, Cancer Treat. Rev, vol.40, pp.109-117, 2014. ,
ATM and ATR as therapeutic targets in cancer, Pharmacol. Ther, vol.149, pp.124-138, 2015. ,
ATR inhibition selectively sensitizes G1 checkpoint-deficient cells to lethal premature chromatin condensation, Proc. Natl. Acad. Sci. USA, vol.98, pp.9092-9097, 2001. ,
ATR mediates cisplatin resistance in a p53 genotype-specific manner, Oncogene, vol.30, pp.2526-2533, 2011. ,
Selective killing of ATM-or p53-deficient cancer cells through inhibition of ATR, Nat. Chem. Biol, vol.7, pp.428-430, 2011. ,
Constant p53 pathway inactivation in a large series of soft tissue sarcomas with complex genetics, Am. J. Pathol, vol.177, pp.2080-2090, 2010. ,
The impact of p53 dysfunction in ATR inhibitor cytotoxicity and chemo-and radiosensitisation, Cancers (Basel), vol.10, p.275, 2018. ,
Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study, BMC Med, vol.15, p.78, 2017. ,
Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas, J. Hematol. Oncol, vol.10, p.84, 2017. ,